Difference between revisions of "Olanzapine-Haloperidol LA"
From Psychiatrienet
(Created page with '{{Drugswitch | from = Olanzapine | to = Haloperidol_LA | stop = {{Downslweeks}} | start = {{StartDepot}} | view = | info = {{Alternatief}} }}') |
(No difference)
|
Revision as of 10:51, 14 August 2009
| ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
Switch medication from Olanzapine to Haloperidol_LA.[7] [8]
Stop Olanzapine - Week 1-3: approx. 75% of initial dose
- Week 4-6: approx. 50% of initial dose
- Week 7-9: approx. 25% of initial dose
- Week 10: stop
Start Haloperidol_LA- Day 1: Start depot according general dosing advice (Dotted line in graph)
More information- Alternatively, first switch to oral form and then switch to depot to manage possible (adverse) reactions. With a direct switch to a depot it is advisable to administer a low testdose in order to exclude adverse reactions.
- ↑ 1.0 1.1 1.2 1.3 KNMP; Informatorium Medicamentorum 2023; Monografie "olanzapine" (Dutch)
- ↑ Farmacotherapeutisch Kompas; Toxicologie (dutch)
- ↑ Woods SW Chlorpromazine equivalent doses for the newer atypical antipsychotics; J Clin Psychiatry 2003;64:663-667
- ↑ WHO Collaborating Centre for Drug Statistics Methodology ATC=N05AD01
- ↑ 5.0 5.1 The Lundbeck Institute; Psychotropics; Terminal Plasma Half-lives
- ↑ 6.0 6.1 Farmacotherapeutisch Kompas; Inleidende Tekst Antipsychotica (dutch)
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
